Publicaciones en colaboración con investigadores/as de Hospital Universitario Príncipe de Asturias (17)

2024

  1. Decrease in active hepatitis C infection among people who use drugs in Madrid, Spain, 2017 to 2023: a retrospective study

    Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, Vol. 29, Núm. 29

  2. Prevalence of HCV Infection Among People Experiencing Homelessness in Madrid, Spain

    JAMA network open, Vol. 7, Núm. 10, pp. e2438657

  3. Recently acquired hepatitis C: Epidemiological characteristics and treatment response in a large cohort of MSM living with HIV in Madrid

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 42, Núm. 8, pp. 414-419

2023

  1. Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients at High Risk of Severe Coronavirus Disease 2019: The PANCOVID Randomized Clinical Trial

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 76, Núm. 3, pp. e116-e125

2022

  1. Metabolic Profiling at COVID-19 Onset Shows Disease Severity and Sex-Specific Dysregulation

    Frontiers in Immunology, Vol. 13

  2. Misdiagnosis rate among negative COVID-19 patients in real-life with Panbio COVID-19 antigen rapid test during 2021

    Journal of Infection

  3. Plasma miRNA profile at COVID-19 onset predicts severity status and mortality

    Emerging microbes & infections, Vol. 11, Núm. 1, pp. 676-688

2021

  1. Age-Adjusted Endothelial Activation and Stress Index for Coronavirus Disease 2019 at Admission Is a Reliable Predictor for 28-Day Mortality in Hospitalized Patients With Coronavirus Disease 2019

    Frontiers in Medicine, Vol. 8

  2. Are Reduced Levels of Coagulation Proteins Upon Admission Linked to COVID-19 Severity and Mortality?

    Frontiers in Medicine, Vol. 8

2020

  1. Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. Drug-related and psychopathological symptoms in HIV-positive men who have sex with men who inject drugs during sex (slamsex): Data from the U-SEX GESIda 9416 study

    PLoS ONE, Vol. 14, Núm. 12

  2. HIV coinfection predicts failure of ledipasvir/sofosbuvir in treatment-naïve noncirrhotic patients with HCV genotype

    Open Forum Infectious Diseases, Vol. 6, Núm. 5

2018

  1. All-oral direct-acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV–coinfected subjects in real-world practice: Madrid coinfection registry findings

    Hepatology, Vol. 68, Núm. 1, pp. 32-47

  2. Increased indoleamine-2,3-dioxygenase activity is associated with poor clinical outcome in adults hospitalized with influenza in the INSIGHT FLU003Plus study

    Open Forum Infectious Diseases, Vol. 5, Núm. 1

  3. Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL study

    PLoS ONE, Vol. 13, Núm. 6

2017

  1. Dual Therapy with Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy with Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial

    Clinical Infectious Diseases, Vol. 65, Núm. 12, pp. 2112-2118

2015

  1. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): A randomised, open-label, non-inferiority trial

    The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 785-792